Title: Ki-67 Expression in Premalignant and Malignant lesions of Gallbladder

Authors: Ajay Kr. Singh, Vivek Choudhary, Mdhu Mati Goel, Vishal Gupta, Preeti Agarwal, Anu Makkar, Vijay Kumar

 DOI:  https://dx.doi.org/10.18535/jmscr/v5i5.50

Abstract

Introduction: Cell proliferation is an important pre-requisite for the development of a neoplasm. Ki-67 is one of the most important cell proliferation markers. Its expression is correlated with the aggression of various histopathologic changes in the epithelium of gallbladder.

Aim: The aim of this study to assess the expression of Ki-67 in various pathological lesions of gallbladder. In the study immunohistochemical expression of Ki-67 was evaluated.

Material and Methods: This  case control study included 154 patients who underwent cholecystectomy for various reasons like carcinoma and cholelithiasis. Out of 154 patients of gall bladder which included 85 cases of malignant lesion (adenocarcinoma) and 47 cases of premalignant and premalignant like lesions (including dysplasia, metaplasia, and xanthogranulomatous cholecystitis) along with 22 cases of chronic cholecystitis as control.

Results: The result showed Ki-67 Li in malignant group, a total of 14 (16.5%) patients had Ki-67 Li expression in range 10-25% and remaining 7 (8.2%) had Ki-67 Li expression >25%. The Ki-67 Li expression was higher for patients aged >40 years, females, with well/ moderately differentiated adenocarcinoma and tumor diameter <2 cm.

Conclusion: The conclusion can be made that Ki-67 can be used as a marker of aggression of gall bladder histopatholgic lesions. 

Keywords:  Gall bladder, Malignancy, Ki-67.

References

1.      Lazcano –Ponce EC, Miquel JF, Munoz N et al. Epidemiology and molecular pathology of gall bladder cancer.  Cancer J Clin 2001;51(6):349-364.

2.      Vitetta L, Sali A, Little P, Mrazek L. Gall stones and gall bladder carcinoma. Aust N z J Surg 2000;70(9):667-73.

3.      Nagahashi M, Ajioka Y, Lang I, Szeintirmay Z. et al. Genetic changes of P53 , K-ras and microsatellite instability in gall bladder carcinoma in high incidence areas of japan and Hungary. World J Gastroenterol 2008;14:70-5.

4.      Lai CH, Lau WY. Gall bladder cancer- a comprehensive review. Surgeon 2008;6(2):101-10.

5.      Ghosh Y, Thakurdas B. Carcinoma gall bladder : A review of literature . Int J Scien Study 2015;2:98-103.

6.      GerdesJ , Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer.1983;31:13-20.

7.      Gerdes J, Lemke H, Baisch H, Walker H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67 .  J Immunol. 1984;41:229-237.

8.      Cattoretti G, Becker MH, Key G et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen ( MIB1 and MIB3 ) detect proliferating cells in microwave –processed formalin-fixed, paraffine sections. J Pathol.1992;168:357-363.

9.      Yerushalmi R, Woods R, Ravdin PM. et al. Ki-67 in breast cancer : prognostic and predictive potential. Lancet Oncol.2010; 11:174-180.

10.  Scholzen T, Gerdes J. “ The Ki-67 protein : from the known and the unknown”. J Cell Physiol.2000 ;182(3):311-322.

11.  Bisgaard LM. Young age colorectal cancer and identification of hereditary non-polyposis colorectal cancer chorts. Br J Surg.2007;94:1055-6.

12.  Bosari S, Monechini L, Graziani D. et al. Bcl-2 oncoprotein in colorectal heperp-lastic polyps, adenoms and adenocar-cinomas. Hum Pathol.1995;26(5):534-540.

13.  Franklin WA, Bibbo M, Doria MI, et al. Quantitation of estrogenrecptor content and Ki-67 staining in breast carcinoma by the micro TICAS image analysis system. Anal quant cytolHistol. 1987;9:279-283.

14.  Kim NK, Park JK, Leek X. P53, Bcl-2 and Ki-67 expression according to tumour response after concurrent chemoradioth-erapy for advanced rectal cancer. Ann Surg. Oncol.2001;8(5):418-422.

15.  Velera V, Yokoyama N, Walter B, Okamoto H. et al. Clinical significance of Ki-67 proliferation index in disease progression and prognosis of patients with resected colorectal carcinoma. Br J Surg.2005;92:1002-7.

16.  Ustymowicz KG, Pryczynicz A, Kemona A et al. Correlation between proliferation markers : PCNA, Ki-67 MCM-2 and anti apoptotic protein bcl2 in colorectal cancer. Anticancer Research 2009;29(8):3049-3052.

17.  Wang X , Zhang J, Chen J. Result of p53, ki67 protein expression in cholangioc-arcinoma with in situ hybridization and immunohistochemistry  methods. Zhongguo Yi Xue Ke Xue Yuan  Xue  Bao. 2000 ; 22(1):57-60.

18.  Spyratos F , FerreroPous M, Trassard M, Hacene K, Phillips E, Tubiana-Hulin M, Le Doussal V. Correlation between MIB1and other proliferation markers: clinical implications of the MIB1 cutoff value. Cancer. 2002 15;94(8):215-19.

19.  Lee CS. Differences in cell proliferation and prognostic significance of proliferatingcell nuclear antigen and Ki67 antigen immunoreactivity in in situ and invasive carcinomas of the extrahepatic biliary tract. Cancer. 1996 ;78(9):1881-7.

20.  Hidalgo Grau LA , Badia JM, Salvador CA, Monsó TS, Canaleta JF, Nogues JM, Sala JS. Gall bladder carcinoma: The role of P53 protein overexpression and Ki67 antigen expression as prognostic markers. HPB (Oxford). 2004;6(3):174-80

21.  Doval DC , Azam S , Sinha R , Batra U , Mehta A. Expression of epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxy-genase2, cyclin D1,  human epidermal receptor2 and Ki67: Association with clinicopathological profiles and outcomes in gallbladder carcinoma. J Carcinog. 2014;13:10.

22.  Xuan YH , Choi YL, Shin YK, Kook MC, Chae SW, Park SM, Chae HB, Kim SH. An immunohistochemical study of the expression of cell-cycle-regulated proteins p53, cyclin D1, RB, p27, Ki67 and MSH2 in gallbladder carcinoma and its precursor lesions. Histol Histopathol. 2005; 20(1):59-66.

Corresponding Author

Dr. Ajay Kr. Singh

Associate Professor, Deptt. of Pathology,

King George,s Medical University (KGMU), Lucknow, UP, India

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.